Idarubicin Hydrochloride

CHEMBL1200976 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
534.0 g/mol
LogP
Phase
4

This is the hydrochloride salt form of idarubicin, an anthracycline antibiotic chemotherapy agent used in the treatment of acute myeloid leukemia. It intercalates into DNA and inhibits topoisomerase II to prevent cancer cell division. Cardiac monitoring is essential as cumulative doses can cause cardiomyopathy.

الوزن الجزيئي

534,0000 g/mol

TPSA

177,00 Ų

المجالات العلاجية

آلية العمل

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl

InChI

InChI=1S/C26H27NO9.ClH/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31;/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3;1H/t10-,15-,16-,17-,21+,26-;/m0./s1

Molecular Formula

C26H28ClNO9

HBD / HBA

6 / 10

الروابط القابلة للدوران

3

الذرات الثقيلة

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This is the hydrochloride salt form of idarubicin, an anthracycline antibiotic chemotherapy agent used in the treatment of acute myeloid leukemia. It intercalates into DNA and inhibits topoisomerase II to prevent cancer cell division. Cardiac monitoring is essential as cumulative doses can cause cardiomyopathy.

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Yes, Idarubicin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200976. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 636362. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.